SST and neoplasm: The superiority of 177Lu-satoreotide tetraxetan over [177Lu]Lu-DOTA-TATE and other SST agonists such as [177Lu]Lu-DOTA-TOC in inhibiting tumour growth was also noted in other in vivo therapy studies, which applied different animal models and treatment regimens [3,4].